Biologics Contract Development Market

Global Biologics Contract Development Market by Sources (Microbial, Mammalian, and Others) Product Services (Cell Line Development [Microbial, Mammalian, and Others], Process Development [Upstream {Microbial, Mammalian, and Others}, Downstream {Impurity, isolation, & identification, Physicochemical characterization, Pharmaceutical analysis, and Others}, Product {MABs, Recombinant proteins, and Others}], and Others), Diseases Indication (Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, and Others), and Regions (Asia Pacific, North America, Europe, Latin America, and Middle East & Africa) Forecasts, 2020-2027

  • Report ID: HC-139
  • Author: Growth Market Reports
  • Rating: 4.8
  • Total Reviews: 0
  • No. Of Pages: 120
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global biologics contract development market is anticipated to expand at substantial CAGR during forecast period, between 2020 and 2027. Biologics contract development organizations (CDOs) are provide full services from cell line production to long-term industrial procurement of biological products. Services include the production of cell lines, upstream and downstream systems, analytical and bioanalytical approaches, formulation and quality evaluation, and regulatory support.

Market Trends, Drivers, Restraints, and Opportunities:

  • Increasing introduction of new technology for biological processing, rising M&A practices, growing outsourcing of R&D operations by pharmaceutical and biopharma firms, and favorable regulatory climate for clinical trials in developing countries are driving the growth of the biologics contract development market.
  • Growing number of mergers and collaborations has expanded the outsourcing of pharmaceuticals and biopharmaceuticals to major manufacturing players in emerging regions.
  • Regulatory authorities in developed countries are harmonizing their regulations with those of the European Medicines Agency (EMA) and The US Food and Drug Administration (FDA) requirements, speeding the approval process, and building legitimacy. The use of contract laboratories for biologics and dependence on clinical trial operations are expected to improve drug processes, thus boosting the market.

Scope of the report:

The report on biologics contract development market includes an assessment of the market, size, share, trends, segments and regional markets. Overview and dynamics have been included in the report.

Attributes Details
Base Year 2019
Historic Data 2017 & 2018
Forecast Period 2020–2027
Regional Scope Asia Pacific, North America, Europe, Latin America, and Middle East & Africa
Report Coverage Market scope, analysis, share, competitive analysis, growth facts, restraints, opportunities and revenue forecast.












 

Biologics Contract Development Market Segment Insights:

The mammalian source segment is projected to hold significant market share

In the terms of sources, the biologics contract development market has been segmented into microbial, mammalian, and others. The mammalian segment is projected to grow at significant pace during the forecast period. This is due to the fact that the use of mammalian cells for protein expression can provide the significant benefit of being able to generate mammalian proteins with all the necessary post-translational modifications to have a native structure.

Demand for process development to fuel segment growth

On the basis of product services, the market has been segregated into cell line development, process development, and others. The cell line development segment is divided into microbial, mammalian, and others. The process development segment is segmented into upstream, downstream, product, and others. The upstream sub-segment is further segmented into microbial, mammalian, and others. The downstream sub-segment is segregated into impurity, isolation, & identification, physicochemical characterization, pharmaceutical analysis, and others. The product sub-segment is further fragmented into MABs, recombinant proteins, and others. The process development segment is projected to expand at a significant pace during the forecast period due to the introduction of emerging innovations, such as automated expression systems, enhanced bioprocessing systems, and single-use technologies to minimize costs and meet the growing demand.

Rising prevalence of immunological disorders propels segment growth

Based on disease indications, the biologics contract development market is fragmented into oncology, immunological disorders, cardiovascular disorders, hematological disorders, and others. The oncology segment holds significant share of the market, while the immunological disorder disease segment is projected to expand at a substantial CAGR during the forecast period. Immunological condition is caused by immune system dysfunction and involves allergies, asthma, and autoimmune diseases, affecting about 7.6% to 9.4% of the world's population.

North America constituted a dominant share of the biologics contract development market

In terms of regions, the global biologics contract development market is classified as North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America accounts for a considerable share of the global market. The development of the CDOs due to increasing outsourcing activities and rising number of clinical trials in the region fuel the market in North America. The demand for biologics contract development in Asia Pacific is expected to rise at a significant pace due to numerous reforms introduced by regulatory organizations to adjust the criteria for clinical trial appraisal in line with global requirements and several major players are investing in the region.

Competitive Landscape:

Key players in the biologics contract development market include Abzena Ltd., AGC Biologics, Bionova Scientific, Boehringer Ingelheim BioXcellence, Fujifilm Diosynth Biotechnologies, Genscript Biotech Corporation, KBI Biopharma, LakePharma, SE Thermo Fisher (Patheon), STC Biologics, Inc., and WuXi Biologics. These players engage in mergers & acquisitions, collaborations, agreements, and partnerships to strengthen their geographical presence.

Segments Covered in the Report

The global biologics contract development market has been divided based on sources, product services, diseases indications, and regions.

By Sources

  • Microbial
  • Mammalian
  • Others

By Product Services

  • Cell Line Development
    • Microbial
    • Mammalian
    • Others
  • Process Development
    • Upstream
      • Microbial
      • Mammalian
      • Others
    • Downstream
      • Impurity, isolation, & identification
      • Physicochemical characterization
      • Pharmaceutical analysis
      • Others
    • Product
      • MABs
      • Recombinant proteins
      • Others
  • Others

By Diseases Indications

  • Oncology
  • Immunological Disorders
  • Cardiovascular Disorders
  • Hematological Disorders
  • Others

By Regions

  • North America
  • Europe
  • Latin America
  • Asia Pacific
  • Middle East & Africa
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Biologics Contract Development Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Biologics Contract Development Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Biologics Contract Development Market - Supply Chain
  4.5. Global Biologics Contract Development Market Forecast
     4.5.1. Biologics Contract Development Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Biologics Contract Development Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Biologics Contract Development Market Absolute $ Opportunity
5. Global Biologics Contract Development Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Biologics Contract Development Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Biologics Contract Development Demand Share Forecast, 2019-2026
6. North America Biologics Contract Development Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Biologics Contract Development Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Biologics Contract Development Demand Share Forecast, 2019-2026
7. Latin America Biologics Contract Development Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Biologics Contract Development Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Biologics Contract Development Demand Share Forecast, 2019-2026
8. Europe Biologics Contract Development Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Biologics Contract Development Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Biologics Contract Development Demand Share Forecast, 2019-2026
9. Asia Pacific Biologics Contract Development Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Biologics Contract Development Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Biologics Contract Development Demand Share Forecast, 2019-2026
10. Middle East & Africa Biologics Contract Development Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Biologics Contract Development Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Biologics Contract Development Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Biologics Contract Development Market: Market Share Analysis
  11.2. Biologics Contract Development Distributors and Customers
  11.3. Biologics Contract Development Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Abzena Ltd.
     11.4.2. AGC Biologics
     11.4.3. Bionova Scientific
     11.4.4. Boehringer Ingelheim BioXcellence
     11.4.5. Fujifilm Diosynth Biotechnologies
     11.4.6. Genscript Biotech Corporation
     11.4.7. KBI Biopharma
     11.4.8. LakePharma
     11.4.9. SE Thermo Fisher (Patheon)
     11.4.10. STC Biologics Inc.
     11.4.11. WuXi Biologics

Segments Covered in the Report
The global biologics contract development market has been divided based on sources, product services, diseases indications, and regions.
By Sources

  • Microbial
  • Mammalian
  • Others


By Product Services

  • Cell Line Development
    • Microbial
    • Mammalian
    • Others
  • Process Development
    • Upstream
      • Microbial
      • Mammalian
      • Others
    • Downstream
      • Impurity, isolation, & identification
      • Physicochemical characterization
      • Pharmaceutical analysis
      • Others
    • Product
      • MABs
      • Recombinant proteins
      • Others
  • Others


By Diseases Indications

  • Oncology
  • Immunological Disorders
  • Cardiovascular Disorders
  • Hematological Disorders
  • Others


By Regions

  • North America
  • Europe
  • Latin America
  • Asia Pacific
  • Middle East & Africa


Key Players in the market

  • Abzena Ltd.
  • AGC Biologics
  • Bionova Scientific
  • Boehringer Ingelheim BioXcellence
  • Fujifilm Diosynth Biotechnologies
  • Genscript Biotech Corporation
  • KBI Biopharma
  • LakePharma
  • SE Thermo Fisher (Patheon)
  • STC Biologics Inc.
  • WuXi Biologics

Buy Report